Researchers from the Institute of Translational Genomics at Helmholtz Munich have described a genetic overlap between type 2 diabetes (T2D), a disease that is also associated with obesity, and osteoarthritis, a degeneration of the joints that worsens with age and coincides in the factor risk of being overweight. The researchers used genetic data, multiomics and functional analysis of the tissues T2D and osteoarthritis express to identify which genes were associated and correlated with both diseases. They published their results on July 10, 2023, in The American Journal of Human Genetics. Read More
Evidence of mitochondrial and lysosome dysfunction underlying Parkinson’s disease (PD) was discussed during several talks at the World Parkinson Congress 2023 (WPC) held in Barcelona. Edward A. Fon, from McGill University in Montreal, explained how eyes turned to mitochondria as key players in PD more than 30 years ago and how the explosion of genetics was fundamental to advance the knowledge and research in PD. Read More
JCR Pharmaceuticals Co. Ltd. has received approval from Germany’s Paul-Ehrlich Institute (PEI) for its clinical trial application (CTA) for JR-441, a blood-brain barrier penetrating form of heparan N-sulfatase developed using JCR’s proprietary J-Brain Cargo technology. Read More
Researchers from Ermium Therapeutics SAS have presented preclinical data for the novel chemokine CXCR4 receptor ligand ER-000145, being developed for the treatment of type 1 interferonopathies, such as systemic lupus erythematosus (SLE). Read More
Beigene Co. Ltd. has identified 3, 4-dihydroisoquinolin-1 (2h)-ones derivatives acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of systemic lupus erythematosus (SLE). Read More
Crossbow Therapeutics Inc. has launched with US$80 million in series A funding. The financing will allow Crossbow to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes on cancer cells, using antibodies that mimic T-cell receptors (TCR). Read More
Salarius Pharmaceuticals Inc. has received FDA clearance of its IND application to initiate a phase I trial with SP-3164 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Read More
National Institute of Pharmaceutical R&D Co. Ltd. has divulged heterocyclic compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB α), AKT2 (PKB β) and AKT3 (PKB γ) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from the University of North Carolina, Chapel Hill and affiliated organizations have reported the development and preclinical evaluation of [18F]F-ZW-cinacalcet, a novel PET agent targeting the calcium-sensing receptor (CaSR) for parathyroid imaging. Read More
Septerna Inc. has closed a US$150 million series B financing and will use the funds to continue development of its portfolio of G protein-coupled receptor (GPCR)-targeted, oral small-molecule drug candidates, including advancement of its lead program targeting the parathyroid hormone 1 receptor (PTH1R) to clinical proof of mechanism. Read More
Novartis AG has described pyridine-3-carboxylate compounds acting as voltage-dependent L-type calcium channel subunit α-1C channel (Cav1.2) activators reported to be useful for the treatment of schizophrenia, major depression, attention deficit hyperactivity disorder, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer’s disease and Brugada syndrome. Read More
